PHARMACY

Pfizer, Medivation to discontinue Dimebon development following late-stage trial results

BY Alaric DeArment

NEW YORK — A late-stage clinical trial to evaluate a drug in Alzheimer’s disease patients came up short, the drug’s developers said Tuesday, prompting them to cease its development.

Pfizer and Medivation announced results of the phase-3 "CONCERT" trial of Dimebon (latrepirdine), a trial that had lasted 12 months and enrolled 1,003 patients worldwide. The drug, which the companies have studied since 2009, was originally developed by Soviet Union scientists in the 1980s as an antihistamine.

The companies said that while the drug appeared safe, it showed no statistically significant improvement in Alzheimer’s disease symptoms. The two said they would discontinue development of the drug for all indications.

Previous studies of the drug have turned up similarly lackluster results. Last April, the companies cancelled the "HORIZON" trial after it failed to show significant improvement in patients with Huntington disease, while the drug also didn’t show a statistically significant improvement in Alzheimer’s patients in the 2010 "CONNECTION" trial.


Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter.

keyboard_arrow_downCOMMENTS

Leave a Reply

starson says:
Jan-18-2012 07:44 am

I was fascinated to discover that there's been research on saffron versus Aricept (donepezil). Check it out: http://nutritionfacts.org/videos/saffron-versus-aricept/. (noncommercial, science-based site) According to the findings, saffron works just as well (which isn't all that well, though better than placebo). And without the side effects.

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

Global head of Sandoz earns spot on ‘Fortune’ list

BY Allison Cerra

HOLZKIRCHEN, Germany — Jeff George, the global head of Sandoz, was ranked No. 9 on Fortune magazine’s annual top “40 under 40” list, a selection of the top 40 young business leaders from a variety of industries.

George, who has served as head of Sandoz since 2008, has led the drug maker to achieve double-digit revenue growth and make significant strides with respect to its differentiated products strategy, particularly in the field of biosimilars, Sandoz said.

Click here to view the full list.


Interested in this topic? Sign up for our weekly Collaborative Care e-newsletter.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

Novo Nordisk partners with Paula Deen in new diabetes initiative

BY Alaric DeArment

PRINCETON, N.J. — Danish drug maker Novo Nordisk is partnering with cooking show host Paula Deen to launch a campaign to help adults find ways to manage challenges associated with Type 2 diabetes, the company said Tuesday.

Deen and her sons, Bobby and Jamie, star in a series of videos as part of the Diabetes in a New Light initiative, in which Deen is sharing her personal diabetes story for the first time.

"I was determined to share my positive approach and not let diabetes stand in the way of enjoying my life," Deen said. "I’m excited to team up with Novo Nordisk on this initiative to show others that managing diabetes does not have to stop you from enjoying the things you love."

The initiative will include resources, such as recipes for dishes that are safe for people with diabetes but don’t compromise taste, instructions on incorporating physical activity into everyday life, managing stress and working with healthcare providers.


Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?